Cat.No: GM-87711MAB
Product: Anti-MSLN hIgG1 Reference Antibody (Anetbio)
Cat.No: GM-87711MAB
Product: Anti-MSLN hIgG1 Reference Antibody (Anetbio)
GM-87711MAB-1mg / 1 mg
GM-87711MAB-5mg / 5 mg
GM-87711MAB-25mg / 25 mg
GM-87711MAB-50mg / 50mg
GM-87711MAB-100mg / 100 mg
Expression System CHO
Aggregation < 5% as determined by SEC-HPLC
Purity > 95% as determined by SDS-PAGE
Endotoxin < 1 EU/mg, determined by LAL gel clotting assay
Sterility 0.2 μm Filtered
Target MSLN
Clone Anetumab
Alternative Names MPF, SMRP
Source/Isotype Human IgG1(K214R), Kappa
Application /
Description MSLN is over expressed in several human tumors, including mesothelioma, ovarian cancer, pancreatic adenocarcinoma, lung adenocarcinoma, and cholangiocarcinoma. MSLN is a tumor differentiation antigen that is normally present on the mesothelial cells lining the pleura, peritoneum and pericardium. Since mesothelin is overexpressed in several cancers and is immunogenic, the protein could be exploited as tumor marker or as the antigenic target of a therapeutic cancer vaccine.
Formulation phosphate-buffered solution, pH 7.4.
Cat.No: GM-87711MAB
Product: Anti-MSLN hIgG1 Reference Antibody (Anetbio)
GM-87711MAB-1mg / 1 mg
GM-87711MAB-5mg / 5 mg
GM-87711MAB-25mg / 25 mg
GM-87711MAB-50mg / 50mg
GM-87711MAB-100mg / 100 mg
Expression System CHO
Aggregation < 5% as determined by SEC-HPLC
Purity > 95% as determined by SDS-PAGE
Endotoxin < 1 EU/mg, determined by LAL gel clotting assay
Sterility 0.2 μm Filtered
Target MSLN
Clone Anetumab
Alternative Names MPF, SMRP
Source/Isotype Human IgG1(K214R), Kappa
Application /
Description MSLN is over expressed in several human tumors, including mesothelioma, ovarian cancer, pancreatic adenocarcinoma, lung adenocarcinoma, and cholangiocarcinoma. MSLN is a tumor differentiation antigen that is normally present on the mesothelial cells lining the pleura, peritoneum and pericardium. Since mesothelin is overexpressed in several cancers and is immunogenic, the protein could be exploited as tumor marker or as the antigenic target of a therapeutic cancer vaccine.
Formulation phosphate-buffered solution, pH 7.4.
